Welcome to Multibagg AI
Log in to access personalized features
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q1 FY26
Investor Presentation
Q4 FY25
Investor Presentation
Q3 FY25
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Discovery themes featuring this stockDiscover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Discovery themes featuring this stockIpca Laboratories Ltd (IPCALAB) is currently trading at 1,470.65 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Ipca Laboratories is a fully integrated Indian pharmaceutical company manufacturing and marketing over 350 formulations and about 80 APIs from 18 Indian manufacturing sites, selling products in more than 100 countries with approvals from major regulators including US FDA, MHRA, ANVISA and TGA and a strong legacy in select APIs such as atenolol and chloroquine. Recent operating momentum: management reported domestic formulations growth of roughly 12% in the quarter, export formulations growth of circa 17% in Q3 and consolidated nine‑month revenue up about 8.4% to INR7,258 crore; standalone and consolidated EBITDA margins improved materially year‑on‑year, driven by mix shifts toward higher‑margin branded and promotional businesses. Strategic and product developments: Ipca has re‑entered and expanded its U.S. generic exposure with around 35 US registrations (five commercialized) and reported a combined U.S. run‑rate near INR395 crore in Q3; the company also disclosed five biosimilar candidates with technology transfer underway, signaling a strategic pivot toward higher value biologic development and global commercialization. Capital and integration posture: management says near‑term organic capex is minimal aside from a planned INR50 crore solar project, while the acquisition and integration of Unichem are expected to improve utilisation and margins over the next two to three years, although Unichem’s near‑term EBITDA will remain under pressure until market share recovers in the U.S.
Over the past 52 weeks, Ipca Laboratories Ltd has traded between a low of ₹1,200.00 and a high of ₹1,594.55. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Ipca Laboratories Ltd has a market capitalization of approximately 37,818.42. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Ipca Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 35.61 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 37,818.42 Cr, Ipca Laboratories Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Ipca Laboratories Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Ipca Laboratories Ltd is 35.61. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
It is a ₹10,000 crore, five-year initiative aimed at making India a global biopharma manufacturing hub by supporting domestic production of biologics, biosimilars, and strengthening the R&D ecosystem.
Concall Transcript
Transcript of Ipca Laboratories' Q3 FY26 earnings call: domestic revenue ~+12%, export formulations Q3 +17%, API Q3 ~flat; standalone EBITDA 26.09% (+~1.8ppt), consolidated EBITDA 22.5% (+~2.3ppt); cash >₹250cr; limited capex.
Concall Transcript
Ipca reported Q3 FY26 results in a Feb 16 concall: domestic sales ~12% growth, export formulations +17% in Q3 (9M INR1,477cr), consolidated 9M revenue up ~8.4% to INR7,258cr, standalone EBITDA 26.09%, consolidated EBITDA 22.5%, healthy cash after land sale and limited capex.
Financial Results
Ipca Laboratories published an extract of unaudited consolidated and standalone Q3 (Dec 31, 2025) and 9M results in newspapers; consolidated revenue Rs2,392.50cr and PAT after tax Rs326.27cr for the quarter; Board approved Feb 13, 2026; limited review unmodified.
Financial Results
Ipca Laboratories published extract of unaudited consolidated and standalone results for quarter and nine months ended Dec 31, 2025: consolidated revenue ₹2,392.50cr (Q3), consolidated PAT ₹326.27cr (Q3) and 9M PAT ₹842.05cr; Board approved Feb 13, 2026; limited review unmodified.
Financial Results
Ipca Laboratories reported standalone and consolidated unaudited Q3FY26 and 9M FY26 results: Q3 revenue Rs 1,845.18 Cr, PBT Rs 417.22 Cr, PAT Rs 303.45 Cr; 9M revenue Rs 5,522.40 Cr, PAT Rs 870.23 Cr; board approved, limited review unmodified.
Financial Results
Ipca Laboratories announced unaudited standalone and consolidated Q3 FY26 results (quarter ended Dec 31, 2025): Q3 revenue Rs1,845.18cr, PBT Rs417.22cr, PAT Rs303.45cr; 9M revenue Rs5,522.40cr, 9M PAT Rs870.23cr; limited review unmodified.
Bearish
2
Neutral
7
Bullish
5
Bearish
10
Neutral
7
Bullish
29
Bearish
8
Neutral
0
Bullish
24
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1171.20 | 67,358 Cr | 19.26 | 1.92 | 0.00 | 9.77 | 12.69 | 6.63 | |
5463.60 | 65,331 Cr | 27.20 | 4.90 | 0.82 | 17.69 | 18.13 | 11.95 | |
2025.00 | 57,267 Cr | 21.11 | 5.98 | 0.12 | 26.24 | 30.84 | 5.60 | |
1039.50 | 56,021 Cr | 66.55 | 11.66 | 0.12 | 14.23 | 15.05 | 8.94 | |
1480.15 | 37,818 Cr | 35.61 | 5.09 | 0.27 | 13.33 | 17.89 | 7.73 | |
166.10 | 22,079 Cr | — | 2.73 | 0.08 | -0.29 | 4.50 | -1.01 | |
773.70 | 15,258 Cr | 22.92 | 2.87 | 1.42 | 11.93 | 12.59 | 7.45 |
Ipca Laboratories is a fully integrated Indian pharmaceutical company manufacturing and marketing over 350 formulations and about 80 APIs from 18 Indian manufacturing sites, selling products in more than 100 countries with approvals from major regulators including US FDA, MHRA, ANVISA and TGA and a strong legacy in select APIs such as atenolol and chloroquine.
Recent operating momentum: management reported domestic formulations growth of roughly 12% in the quarter, export formulations growth of circa 17% in Q3 and consolidated nine‑month revenue up about 8.4% to INR7,258 crore; standalone and consolidated EBITDA margins improved materially year‑on‑year, driven by mix shifts toward higher‑margin branded and promotional businesses.
Strategic and product developments: Ipca has re‑entered and expanded its U.S. generic exposure with around 35 US registrations (five commercialized) and reported a combined U.S. run‑rate near INR395 crore in Q3; the company also disclosed five biosimilar candidates with technology transfer underway, signaling a strategic pivot toward higher value biologic development and global commercialization.
Capital and integration posture: management says near‑term organic capex is minimal aside from a planned INR50 crore solar project, while the acquisition and integration of Unichem are expected to improve utilisation and margins over the next two to three years, although Unichem’s near‑term EBITDA will remain under pressure until market share recovers in the U.S.
Pharmaceuticals
Pharmaceuticals - Indian - Bulk Drugs & Formln Lrg
37,818 Cr
Low Risk
35.6
26.5
1.6
5.1
1,594.55
1,200.00
Sales CAGR
Profit CAGR
ROE
ROCE
